Spyre Therapeutics develops long-acting antibody therapies and antibody combinations for inflammatory bowel disease and rheumatic diseases. The company’s pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A and IL-23, with programs such as SPY001, SPY002 and SPY003 evaluated as monotherapies and pairwise combinations.
Recurring news for Spyre Therapeutics includes clinical updates from the SKYLINE platform trial in ulcerative colitis and the SKYWAY basket trial in rheumatic diseases, financial results and corporate updates, common-stock financing activity, and equity inducement awards under its 2018 Equity Inducement Plan. Company announcements also describe balance-sheet actions, development priorities and data presentations tied to its immune-mediated disease pipeline.
Spyre Therapeutics (SYRE) reported third-quarter financial results and clinical updates, including a $96.1 million net loss and discontinued rheumatic-disease development.
The loss widened from $11.2 million a year earlier. All three SKYLINE monotherapies met their primary endpoints in ulcerative colitis; randomized combination induction results are expected in Q3 2027. SPY072 missed primary endpoints in psoriatic arthritis and axial spondyloarthritis, while rheumatoid arthritis results fell below the company's advancement threshold.
Spyre initiated the Phase 2 SKYLIGHT combination study in hidradenitis suppurativa and plans pivotal SPY072 monotherapy studies in 2027. September 30 cash, cash equivalents and marketable securities were $1,071.9 million; pro forma funds were $1,467.9 million including October financing. The company expects this funding to support operations into the second half of 2029.
Spyre Therapeutics (NASDAQ: SYRE) announced clinical and preclinical presentations covering its investigational inflammatory bowel disease antibodies at United European Gastroenterology Week 2026.
The Barcelona presentations include the first scientific congress presentation of clinical data across SPY001, SPY002 and SPY003. All three are being tested individually and in two-antibody combinations in the SKYLINE study. The October 18 oral presentation covers efficacy and safety for induction treatment of moderately to severely active ulcerative colitis. An October 19 poster covers preclinical findings in humanized mice with experimentally induced colitis, including improved efficacy with combinations. Spyre described the preclinical combination effects as additive; no numerical clinical or preclinical results were disclosed.
Spyre Therapeutics (SYRE) priced its previously announced underwritten public offering of common stock at $85.00 per share to raise additional capital. The offering comprises 4,117,648 shares, with expected gross proceeds of approximately $350.0 million before underwriting discounts, commissions and other offering expenses. Underwriters have a 30-day option to purchase up to an additional approximately $52.5 million of shares on the same terms.
Spyre expects closing on or about October 7, 2026, subject to customary closing conditions. It intends to fund development across Gastroenterology, Rheumatology and Dermatology, including preclinical studies, clinical trials, manufacturing and Phase 3 readiness, plus a new program to advance SPY072 into late-stage development for hidradenitis suppurativa.
Spyre Therapeutics (SYRE) has commenced a proposed underwritten public offering of common stock to fund continued development of its programs. The company expects to grant underwriters a 30-day option to purchase an additional 15% of the shares offered on the same terms. Completion is subject to market and other conditions.
Spyre intends to use net proceeds to advance Gastroenterology, Rheumatology and Dermatology programs through preclinical studies, clinical trials, manufacturing and Phase 3 readiness. Proceeds would also support a new program to advance SPY072 into late-stage development for hidradenitis suppurativa. Jefferies, TD Cowen, Leerink Partners and Stifel are joint book-running managers; LifeSci Capital is passive bookrunner.
Spyre Therapeutics (SYRE) approved equity inducement awards for two non-executive employees, including stock options to purchase 21,424 common shares.
The awards also include 6,604 restricted stock units (RSUs) and were approved on October 1, 2026 under the amended 2018 Equity Inducement Plan. They were material to the employees’ acceptance of employment. The options have a $89.93 exercise price, equal to the October 1 closing share price, and a 10-year term. Options vest one-fourth on the first anniversary of each employee’s start date, then one-forty-eighth monthly. RSUs vest one-fourth annually on anniversaries of the next specified quarterly date on or after the employee’s start date. Both awards require continuous service through their vesting dates.
Spyre Therapeutics (SYRE) reported positive 12‑week Part A induction results from the Phase 2 SKYLINE trial of SPY003, its extended half-life anti‑IL‑23 antibody for moderately‑to‑severely active ulcerative colitis.
SPY003 met the primary endpoint with a statistically significant 10.0‑point reduction in Robart’s Histopathology Index (RHI) at Week 12 (p<0.0001), alongside secondary outcomes of 20% clinical remission and 30% endoscopic improvement and a 3.5‑point mean decline in modified Mayo Score. The safety profile was consistent with the IL‑23 class: 43% of patients experienced treatment‑emergent AEs, 11% had severe AEs, 2% had drug‑related AEs, and there were no drug‑related serious AEs, discontinuations, or deaths.
With prior positive data for SPY001 (anti‑α4β7) and SPY002 (anti‑TL1A), Spyre now has clinical proof‑of‑concept for all three inflammatory bowel disease components, supporting enrollment of SKYLINE Part B combination cohorts, with topline induction data expected in 2027.
Spyre Therapeutics (SYRE) granted inducement equity awards to a new non-executive employee, consisting of options to purchase 2,106 common shares and 745 restricted stock units under its 2018 Equity Inducement Plan. The awards were approved on September 1, 2026 in line with Nasdaq Listing Rule 5635(c)(4).
The stock options have a 10-year term and an exercise price of $88.50, equal to Spyre’s September 1, 2026 closing share price. Options vest 25% on the first anniversary of the employee’s start date, with the remaining 75% vesting monthly over the next three years, subject to continuous service. RSUs vest in four equal annual installments on specified quarterly vesting dates following the start date, also contingent on continued service.
Spyre Therapeutics (SYRE)/b) will participate in three investor conferences in September 2026, including events hosted by Citi, Wells Fargo, and Stifel, featuring fireside chats on September 9, 10, and 23.Management will also hold one-on-one investor meetings, with live audio webcasts and replays available on Spyre’s investor events website.
Spyre Therapeutics (NASDAQ: SYRE) reported topline results from the rheumatoid arthritis (RA) sub-study of its Phase 2 SKYWAY basket trial of TL1A antibody SPY072. The low dose achieved a statistically significant improvement vs placebo on the primary endpoint DAS28-CRP at Week 12 (-1.9 vs -1.3; p<0.05). High-dose SPY072 showed nominally significant benefit on ACR20 (63% vs 43%), while low dose showed nominally significant benefit on ACR50 (38% vs 19%). Both doses reached target drug levels and provided complete suppression of free TL1A through Week 12, indicating full target engagement.
SPY072 was well tolerated, with adverse events in 27% of active vs 36% of placebo patients, mostly mild or moderate; one serious TEAE occurred per arm, none drug-related, and one death occurred on placebo. Spyre said the efficacy magnitude did not meet its internal bar to prioritize SPY072 RA monotherapy, but the data support broader TL1A potential and ongoing trials in PsA, axSpA, ulcerative colitis and hidradenitis suppurativa, with multiple topline readouts expected from late 2026 through 2028.
Spyre Therapeutics (NASDAQ: SYRE) announced the launch of SPY772, a long-acting combination program pairing SPY072, an anti‑TL1A antibody, with SPY007, a novel anti‑IL‑17A/F antibody, for Hidradenitis Suppurativa (HS).
The company also initiated SKYLIGHT, a randomized, placebo-controlled Phase 2 proof‑of‑concept trial in approximately 150 adults with moderate‑to‑severe HS. All participants will receive background bimekizumab, plus either SPY072 or placebo. The primary endpoint is Week 16 HiSCR75 response, with topline data planned for late 2027 or early 2028. According to Spyre Therapeutics, positive SKYLIGHT data could support advancement of the long‑acting SPY772 coformulation in HS and exploration of additional indications.